Takeda Pharmaceutical Company Limited (TAK) - Stock Analysis
Last updated: Sep 19, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Broke above its prior 21-session high on October 30 after gaining about 17% over the period. Takeda beat second-quarter adjusted earnings forecasts and raised its outlook, alongside positive product and pipeline updates.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Improvement ⢠Liquidity Pressure ⢠High Intangibles TAK shows stronger quarterly margins and solid cash generation, but weakening liquidity, rising leverage, heavy intangibles, and a high earnings multiple warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠$19.05 resistance ⢠$18.60 support Support Level: $18.60â$18.70; secondary $18.10â$18.25 Resistance Level: $19.05 TAK is in a constructive uptrend over the last month, but traders should watch for a break above $19.05 or protect against weakness below $18.60.
Sentiment & News
Key News Insights: ⢠Regulatory momentum ⢠Pipeline expansion ⢠Strategic partnerships Takeda's FDA/Japan approvals, priority review, and strategic partnerships strengthen its growth pipeline and commercial outlook.
AI Summary
Takeda is no longer a defensive cash-flow value play but a launch-execution story: upside depends on MIMRYLO, ORZEYFUL, and especially zasocitinib translating approvals and pipeline promise into sustained revenue, margins, and deleveraging, while high debt and intangible-asset exposure amplify the cost of disappointment.
Description
Takeda Pharmaceutical Company Limited is a global pharmaceutical firm headquartered in Tokyo that researches, develops, manufactures and commercializes medicines across major markets including Japan, North America, Europe, Latin America and Asia. Its portfolio spans gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience, supported by marketed brands and a pipeline of partnered programs. The company maintains numerous licensing and research collaborations with academic centers and biopharma firms to supplement internal development efforts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 30 | Nov 6 | TAK | Takeda Pharmaceutical Company Limited | Broke above its prior 21-session high on October 30 after gaining about 17% over the period. Takeda beat second-quarter adjusted earnings forecasts and raised its outlook, alongside positive product and pipeline updates. | Active | +0.0% |